Table 1.
Distribution of the studied cases according to sex and type of vaccine
| Vaccine | Study group (n = 2000) | P-value | ||
|---|---|---|---|---|
| Number | Female | Male | ||
| AstraZeneca | n = 524 | 248 (47.3%) | 276 (52.7%) | |
| Johnson and Johnson | n = 32 | 8 (25%) | 24 (75%) | |
| Moderna | n = 12 | 1 (8.3%) | 11 (91.7%) | |
| Pfizer | n = 68 | 12 (17.6%) | 56 (82.4%) | X2 = 96.11 |
| Sinopharm | n = 476 | 200 (42%) | 276 (58%) | P-value < 0.001 |
| Sinovac | n = 416 | 144 (34.6%) | 272 (65.4%) | |
| Sputnik | n = 380 | 208 (54.7%) | 172 (45.3%) | |
| Sputnik light | n = 92 | 13 (14.1%) | 79 (85.9%) | |
X2: chi-square test. P-value < 0.05 is considered significant